02157 樂普生物－Ｂ
按盘价 
3.250 +0.020 (+0.619%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -0.899% | -29.886% | -44.877% | -29.469% | -29.308% |
| 股东资金回报率 (%) | -2.458% | -79.316% | -87.524% | -103.808% | 126.819% |
| 资本运用回报率 (%) | -1.488% | -40.884% | -65.949% | -28.503% | -144.370% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 87.452% | 87.124% | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | 47.645% | -3911.097% | N/A | N/A | N/A |
| 税前边际利润率 (%) | -13.446% | -4491.658% | N/A | N/A | N/A |
| 纯利率 (%) | -9.805% | -4424.942% | N/A | N/A | N/A |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 0.753 X | 0.963 X | 0.572 X | 2.206 X | 0.182 X |
| 速动比率 (X) | 0.720 X | 0.935 X | 0.528 X | 2.155 X | 0.176 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 62.727% | 64.385% | 59.315% | 38.038% | 112.171% |
| 总债项 / 总资产比率 (%) | 31.110% | 27.027% | 15.905% | 8.222% | 37.678% |
| 净债项 / 总资产比率 (%) | 13.242% | 0.560% | 8.452% | -8.401% | 25.317% |
| 总债项 / 股东资金比率 (%) | 82.702% | 75.887% | 39.577% | 13.523% | N/A |
| 长期债项 / 股东资金比率 (%) | 31.685% | 32.545% | 30.111% | 12.270% | N/A |
| 净债项 / 股东资金比率 (%) | 35.203% | 1.573% | 21.032% | -13.817% | N/A |
| 净现金 / (债项) ($) | (3.16亿) | (1.42千万) | (1.76亿) | 2.04亿 | (3.86亿) |
| 每股净现金 / (债项) ($) | (0.190) | (0.009) | -- | -- | -- |
| 总债项 / 资本运用比率 (%) | 49.958% | 40.558% | 21.601% | 9.761% | 185.600% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 345.115日 | 4391.378日 | -- | -- | -- |
| 应收贸易帐周转率日数 (日) | 33.076日 | 71.256日 | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 302.671日 | 3808.299日 | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为14/11/2024 12:27 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -192,430,000 |
| 增长率 | 35.606% |
| 每股盈利/(亏损) | RMB -0.120 |
| 每股账面资产净值 (¥) | RMB 0.535 |